Post Type Archives: News

Novartis announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in […]

• The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities • Lonza reports 2024 financials for the CDMO Business Platforms for sales, CORE EBITDA, CORE EBITDA margin and CapEx for the purpose of comparison ahead of reporting its Half-Year 2025 […]

Siegfried expands capacity for eye drop production at its manufacturing site in El Masnou, Spain  Expansion complements the ongoing capacity extension for sterile eye care ointments in El Masnou  Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in […]

CPHI & PMEC China (June 24-26th) returns to the Shanghai New International Expo Center amid a marked surge in international interest, with industry momentum rebounding following a string of positive developments in global trade and pharmaceutical investment. The 2025 edition is set to become the largest pharma event ever held in Asia, with more than […]

Ingenza is delighted to announce its relocation to The Moubray Building at Edinburgh Technopole, part of the Pioneer Group. The new site is still within the Midlothian Science Zone – a world-leading centre of research excellence in life sciences – and is now fully operational, marking a significant milestone in the company’s continued growth. Ingenza […]

Shilpa Biologicals – a full-service contract development and manufacturing organization (CDMO) – announces the opening of a dedicated bioconjugation suite at its Dharwad site [India]. Located adjacent to the company’s existing commercial biologics manufacturing facility, the suite is currently undergoing validation and is expected to begin onboarding client programs by September 2025. This latest expansion […]

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena’s scientific and […]

Lonza has appointed Andreas Bohrer to the newly created role of Chief Legal & Corporate Affairs Officer. Effective 1 July 2025, Andreas will also become a member of the company’s Executive Committee (EC). Andreas has served as Lonza’s Group General Counsel and Company Secretary since 2015. During his tenure, he has overseen the company’s Legal, […]

Terumo Corporation announced that it has reached an agreement with WuXi Biologics for Terumo to acquire WuXi Biologics’ drug product (DP) plant located in Leverkusen, Germany for 150 million Euro (about 24.6 billion yen*1). Terumo develops containers such as prefilled syringes and drug delivery devices using materials suitable for pharmaceuticals. The company also engages in […]

Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, […]